New CAR-T therapy takes on stubborn blood cancers in early trial
NCT ID NCT07200479
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 31 times
Summary
This early-phase study tests a new treatment called CT1194D CAR-T cells in 20 adults with B-cell blood cancers that have come back or not responded to standard therapy. The main goals are to check safety and find the best dose, while also measuring how well it shrinks tumors. Participants receive a single infusion of their own engineered immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.